Bayer, CRISPR to create JV to develop new gene therapies
The JV will unite CRISPR Therapeutics’ CRISPR-Cas9 gene editing technology with Bayer’s protein engineering and disease expertise. Bayer will invest a minimum of $300m in the JV over
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
The filter dryer, first introduced early this year, provides a completely closed system unit for isolation and drying, which minimizes operator exposure and provides a safer manufacturing environment.
Keith Flaherty, M.D., Director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital and Associate Professor at Harvard Medical School has been named the Principal Investigator.
This approval marks the second FDA-approved indication in advanced melanoma for KEYTRUDA, which is now the first anti-PD-1 therapy approved for previously untreated advanced melanoma patients regardless of